Pay in 4 interest-free payments of $6.84 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
The GLP-1 receptor/GIP receptor/GCGR triple agonist efocipegtrutide is presently under investigation in individuals with MASLD, and preclinical accounts of other dual and triple agonists that include GLP-1 receptor and GCGR agonism suggest that clinical studies in individuals with type 2 diabetes will follow [62, 63]
This surge was driven by robust demand in both the US and international markets, with US sales growing by 41% and ex-US sales by 26% in constant currencies
Its important to explore your options and choose the medication that feels like the perfect fit for your goals and long-term success
We've created a detailed info sheet download to lay out these new vial options and how they can benefit you and your patients: For Providers and Patients: We created this informational breakdown that can easily be distributed from your office straight to your patients
This gives you the evidence you need for a productive discussion with a healthcare provider, armed with facts, not just feelings
